Sixth Street, a private equtiy firm, and Royalty Pharma, a company which is engaged in investing in late stage biopharmaceutical products, completed an $1.25bn investment in Blueprint Medical, a company which engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets. "This attractive deal puts Blueprint Medicines in a very strong financial position to drive rapid growth while maintaining our path to profitability in the coming years. The combination of our strong cash position, multiple drivers of top-line revenue, and diversity of important pipeline programs uniquely positions us to continue building a leading precision therapy company and bring transformative medicines to patients worldwide. Executing this deal with such favorable terms in the current market environment speaks to the quality of the assets, the aligned confidence in the commercial opportunities, and the investment opportunity that Blueprint Medicines represents overall for firms like Sixth Street and Royalty Pharma, with whom we are building long-term strategic relationships," Kate Haviland, Blueprint Medicines Chief Executive Officer.